$1.090
-0.010 (-0.91%)At close
- High
- 1.130
- Open
- 1.100
- VWAP
- 1.10
- Vol
- 19.95K
- Mkt Cap
- 39.68M
- Low
- 1.080
- Amount
- 21.94K
- EV/EBITDA, TTM
- -0.69
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Valuation Metrics
Events Timeline
News
9.006-03NewsfilterIN8bio Publishes Review on γδ T Cell Therapies
- 9.006-01Newsfilter
IN8bio Updates Clinical Data on DeltEx DRI Therapy
9.505-08seekingalphaIN8bio Reports Q1 Loss but Promising Data Ahead
- 9.505-07Newsfilter
IN8bio Advances γδ T Cell Engager Platform with Promising Data
- 9.503-12seekingalpha
IN8bio Reports FY Loss and Launches $40.2M Private Placement
INAB FAQ — answered by Alphio AI
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.